UNITING EXPERTISE. ACCELERATING DISCOVERY.

Cell and Gene Therapy Development

Noble Life Sciences, in collaboration with Accelevir, provides specialized services for cell and gene therapy development, from lab to clinic. Our offerings include detailed cell product characterization—covering vector integrity, gene editing efficiency, and integration site analysis—and advanced tumor efficacy models using bioluminescent and humanized systems. Through this new partnership, we are equipped to facilitate the transition of biomarker assays into clinical trials ultimately enhancing patient outcomes.

We ensure the creation of unique models for:

A PARTNERSHIP TO BENEFIT OUR CLIENTS

Accelevir, a Maryland-based biotechnology company, develops and enables innovative assays for ultra-rare analytes. Driven by a strong scientific ethos with continual advancement of our operational standards, they advance disruptive technologies to market for enabling cure programs.

In collaboration with Accelevir, Noble Life Sciences provides a new range of services for cell and gene therapy development. Reach out to our experts to discuss your specific needs.

  • Cell Product Characterization
    • Vector Copy Number and Integrity
    • Gene Editing Efficiency
    • Integration Site Analysis
  • Multiple Tumor Efficacy Models
    • Bioluminescent and Humanized Models
  • GLP Biodistribution, Persistence & Shedding
    • Multiplex Digital & Quantitative PCR for Rare Targets
  • Translate Your Biomarker Assays from Preclinical to Clinical Trials
    • PBMC Processing, Phenotyping, and Storage

With over 25 years of experience, our team brings extensive expertise in drug development, cell and gene therapy, vaccine research, and medical device innovation.

Together, this partnership expands our capabilities to include IND enabling and clinical biomarker studies and enhances our comprehensive suite of services for the development of drugs, vaccines, and medical devices, providing seamless support from preclinical phases through clinical needs. Whether you’re advancing drug candidates or developing innovative medical technologies, our joint expertise is here to accelerate your path to clinical success.

Contact Us to Receive a Custom Quote

Our Services

for Cell & Gene Therapy Development

Noble Life Sciences is a full-service preclinical contract research organization offering GLP and non-GLP services, including safety and efficacy testing, for the development of drugs, vaccines, and medical devices.

IND Enabling Studies For Cell & Gene Therapy

  • Biodistribution & Persistence Studies
    • Digital PCR & Quantitative PCR
    • Flow Cytometry
  • Safety Studies
    • Tumor Bearing Models
    • Humanized Mouse Models
  • Therapeutic Agents
    • Cell-based Therapeutics (CAR-T, IPSC)
    • Cancer Vaccines
    • Nucleic Acid Vaccines & Therapeutics
    • Nanoparticle Vaccines & Therapeutics
    • Viral-derived Gene Therapies (AAV, Adeno, Lenti)

Oncology CRO Services

  • GLP and Non-GLP Toxicology Studies
  • Mouse Efficacy Models
    • Xenograft
    • Syngeneic
    • Humanized Mice
    • Orthotopic Implantation
    • Bioluminescent Tumor Models
  • Assay Services
    • Digital PCR
    • Quantitative PCR
    • Flow Cytometry
    • Immunophenotyping
    Oncology Drug Testing  cover thumbnail

    Preclinical Capabilities Sheet

    Oncology Drug Testing  cover thumbnail

    Cell & Gene Capabilities Sheet

    Cell & Gene Therapy

    Scientific Advisor Team

    Our oncology team is committed to fight The Fight by advancing your preclinical research.

    Stephen K. Horrigan, Ph.D.

    Stephen K. Horrigan, Ph.D.

    Chief Scientific Officer

    Pang-Kuo Lo, Ph.D. MSc

    Pang-Kuo Lo, Ph.D. MSc

    Team Lead, Assay Development

    Arundhati Ghosh, Ph.D., MSc

    Arundhati Ghosh, Ph.D., MSc

    Study Director

    Yongping Chen, M.D., Ph.D.

    Yongping Chen, M.D., Ph.D.

    Senior Study Director